Skip to main content
Clinical Trials/NCT01131468
NCT01131468
Completed
Phase 2

The Evaluation of the Protective Effect of N-Acetylcysteine Against Drug Induced Ototoxicity in Peritoneal Dialysis Patients

TC Erciyes University1 site in 1 country60 target enrollmentStarted: February 2008Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
60
Locations
1

Overview

Brief Summary

The purpose of this study is to determine whether N-acetylcysteine is effective in the prevention of hearing loss in both ears due to aminoglycoside and/or vancomycine induced ototoxicity in peritoneal dialysis patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • End-stage renal disease
  • Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy
  • Clinical diagnosis of a peritonitis episode in a continuous ambulatory peritoneal dialysis patient
  • Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode

Exclusion Criteria

  • Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months
  • Detection of mechanical occlusion of external ear
  • Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry
  • History of a continuous ambulatory peritoneal dialysis related peritonitis

Arms & Interventions

Controls

No Intervention

Vancomycine and/or amikacin alone

Intervention: N-acetylcysteine (Drug)

N-acetylcysteine

Experimental

N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin

Intervention: N-acetylcysteine (Drug)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials